Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>MRI‐based radiomics has been used to diagnose breast lesions; however, little research combining quantitative pharmacokinetic parameters of dynamic contrast‐enhanced MRI (DCE‐MRI) and diffusion kurtosis imaging (DKI) exists.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To develop and validate a multimodal MRI‐based radiomics model for the differential diagnosis of benign and malignant breast lesions and analyze the discriminative abilities of different MR sequences.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Study Type</h3><p>Retrospective.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Population</h3><p>In all, 207 female patients with 207 histopathology‐confirmed breast lesions (95 benign and 112 malignant) were included in the study. Then 159 patients were assigned to the training group, and 48 patients comprised the validation group.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Field Strength/Sequence</h3><p>T<sub>2</sub>‐weighted (T<sub>2</sub>W), T<sub>1</sub>‐weighted (T<sub>1</sub>W), diffusion‐weighted MR imaging (b‐values = 0, 500, 800, and 2000 seconds/mm<sup>2</sup>) and quantitative DCE‐MRI were performed on a 3.0T MR scanner. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Assessment</h3><p>Radiomics features were extracted from T<sub>2</sub>WI, T<sub>1</sub>WI, DKI, apparent diffusion coefficient (ADC) maps, and DCE pharmacokinetic parameter maps in the training set. Models based on each sequence or combinations of sequences were built using a support vector machine (SVM) classifier and used to differentiate benign and malignant breast lesions in the validation set. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Statistical Tests</h3><p>Optimal feature selection was performed by Spearman's rank correlation coefficients and the least absolute shrinkage and selection operator algorithm (LASSO). Receiver operating characteristic (ROC) curves were used to assess the diagnostic performance of the radiomics models in the validation set.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The area under the ROC curve (AUC) of the optimal radiomics model, including T<sub>2</sub>WI, DKI, and quantitative DCE‐MRI parameter maps was 0.921, with an accuracy of 0.833. The AUCs of the models based on T<sub>1</sub>WI, T<sub>2</sub>WI, ADC map, DKI, and DCE pharmacokinetic parameter maps were 0.730, 0.791, 0.770, 0.788, and 0.836, respectively. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Data Conclusion</h3><p>The model based on radiomics features from T<sub>2</sub>WI, DKI, and quantitative DCE pharmacokinetic parameter maps has a high discriminatory ability for benign and malignant breast lesions. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Level of Evidence</h3><p>3</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Technical Efficacy Stage</h3><p>2</p></section>

Quantitative MRI Radiomics in the Prediction of Molecular Classifications of Breast Cancer Subtypes in the TCGA/TCIA Data Set

Radiomic Analysis Reveals DCE-MRI Features for Prediction of Molecular Subtypes of Breast Cancer.

MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence As Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.

Predicting Breast Cancer Subtypes Using Magnetic Resonance Imaging Based Radiomics with Automatic Segmentation.

Machine Learning-Based Analysis of MR Multiparametric Radiomics for the Subtype Classification of Breast Cancer.

Exploration of a noninvasive radiomics classifier for breast cancer tumor microenvironment categorization and prognostic outcome prediction

Radiogenomics Analysis Reveals the Associations of Dynamic Contrast-Enhanced–mri Features with Gene Expression Characteristics, PAM50 Subtypes, and Prognosis of Breast Cancer

Molecular Subtypes Recognition of Breast Cancer in Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging Phenotypes from Radiomics Data

Quantitative MRI-based Radiomics for Noninvasively Predicting Molecular Subtypes and Survival in Glioma Patients

Radiomics Analysis on Ultrasound for Prediction of Biologic Behavior in Breast Invasive Ductal Carcinoma

Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer

Unsupervised Analysis Based on DCE-MRI Radiomics Features Revealed Three Novel Breast Cancer Subtypes with Distinct Clinical Outcomes and Biological Characteristics

Prediction Breast Molecular Typing of Invasive Ductal Carcinoma Based on Dynamic Contrast Enhancement Magnetic Resonance Imaging Radiomics Characteristics: A Feasibility Study

Using ensemble learning and genetic algorithm on magnetic resonance imaging radiomics to classify molecular subtypes of breast cancer

Radiogenomic analysis of breast cancer: Dynamic contrast enhanced - Magnetic resonance imaging based features are associated with molecular subtypes

Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer

Quantitative diffusion weighted imaging parameters in tumor and peritumoral stroma for prediction of molecular subtypes in breast cancer

Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer

Radiomics Based on Multimodal MRI for the Differential Diagnosis of Benign and Malignant Breast Lesions

Predicting the Level of Tumor-Infiltrating Lymphocytes in Patients with Breast Cancer: Usefulness of Mammographic Radiomics Features.

Intra- and Peritumoral Radiomics on Assessment of Breast Cancer Molecular Subtypes Based on Mammography and MRI.